Monoclonal antibodies and antivirals certainly represent the injection of the potency that is needed in the so-called “route of treatment” against COVID-19, the other more vigorous avenue represented by vaccines against the SARS-COV-2 virus. lagged behind. , That every day expands its portfolio with more than 10 approved developments and they are made available on different platforms.
AstraZeneca’s scientific innovation reinforces these ideas with the discovery presented to the world today, and after gaining new scientific evidence through two Phase III clinical trials (PROVENT and TACKLE), known as the Anglo-Swedish The company had put in the study :Se is about a cocktail of two monoclonal antibodies against COVID-19 that A strong efficacy of 83% was shown after applying a single intramuscular (IM) dose of the long-acting antibody combination. That is, it reduces the risk of developing symptomatic COVID-19 by 83 percent in six months.
YouNot among the great successes of this therapy, which is called AZD7442 hey evusheld is that it is the only long-acting antibody with phase III data demonstrating its benefit in pre-exposure prophylaxis and treatment of COVID-19 with a single dose.
This drug combination, A 300 mg dose of AZD7442 that is composed of Administered intramuscularly (IM), it is being studied for early prophylaxis (prevention) of exposure to the SARS-CoV-2 virus in high-risk and immunosuppressed people.or infected; Groups that do not respond well to vaccines (preventive action) and infected people (treatment).
The six-month follow-up of the Prevention Study (PROVENT) showed an 83% reduction in the risk of symptomatic COVID-19 with AZD7442, with no cases of serious illness or death. And the Separate Treatment Study (TACKLE) showed an 88% reduction in the risk of severe COVID-19 or death if treated within three days of the onset of symptoms.
in exclusive conversation with infobae doctor from mexico Jesus Abraham Simon Farm, Founder and Principal Investigator of Kohler & Milstein Research and Emeritus Researcher at Augustin O’Horan Hospital, Merida, Mexico Explained, “K Avenue the treatment is uncovered and has both monoclonal and antiviral antibodies They are in an accelerated stage to seek approval from regulatory agencies. While the vaccine remains the fundamental pivot against COVID-19, scientists must continue to work to help all understand the social value of vaccination; complement and expand the windows of immunity and protection against viruses allowing treatment with monoclonal and antiviral antibodies, Son the treatment Determining the factors to stop the epidemic, which is what we do for the longest time”,
It is believed that about 2% of the world‘s population passed an increased risk of inappropriate response to the COVID-19 vaccine, What people with blood cancer or other tumors who are being treated with chemotherapy, in patients dialysis, ns what are you drinking Medicine after an organ transplant or who are taking immunosuppressant drugs For conditions including multiple sclerosis and rheumatoid arthritis.
As warned by expert Simon Campos infobae, “Present A population group that does not respond well to vaccination for a variety of reasons. When antibodies are given to these high-risk subjects before developing COVID-19, they can protect them for up to twelve months. with this, The versatility of the drug allows it to be used even for the treatment of disease.
This type of progress on the pandemic allows us to point out that En refers to the various innovations surrounding scientific research and quest to achieve the best strategies to contain the pandemic, Latin America has been an undisputed hero”.
according to the data you have accessed Infobae, there were no cases of severe COVID-19 or COVID-19-related deaths among those treated with AZD7442, Neither in the first nor in the six months of research. In the meantime, There were two more cases of severe COVID-19 among those receiving placebo In the six months assessment, for a total Five cases of severe COVID-19 and two deaths with COVID-19.
Additionally, in another trial of outpatient treatment (TACKLE) in mild to moderate COVID-19 patients, 600 mg intramuscular dose of AZD7442 was shown to reduce the risk of severe COVID-19 or death (for whatever reason) from 88% compared to placebo in patients who were symptomatic for three days or less at the time of treatment.90% of the participants enrolled in this study had severe COVID-19. were from populations at high risk of progression to If they become infected, including those with co-morbidities.
“These convincing results assures me that this long-acting antibody combination can provide vulnerable patients with the long-lasting protection they urgently need to return to their daily lives, it is important to note that Six months of protection was maintained despite the increase in the Delta version. of these high-risk participants who may not respond adequately to vaccination,” he remarked Hugh Montgomery, Professor of Intensive Care at University College London (UK) and principal investigator of AZD7442.
AZD7442 It is the only long-acting antibody with phase III data demonstrating benefit in both pre-exposure prophylaxis and single-dose treatment of COVID-19. This new data adds to a growing body of evidence supporting the potential of AZD7442 to make a significant difference in the prevention and treatment of COVID-19. We are making progress in filing regulatory applications around the world and look forward to offering a significant new alternative against SARS-CoV-2 as soon as possible.” added to the Executive Vice President of AstraZeneca Biopharmaceutical R&D, Maine Pangalos.
The full results of these two studies The company said they would be submitted for publication in a peer-reviewed medical journal and presented at an upcoming medical meeting.
Last October 5, astraZeneca announced that he had submitted An application to the United States Food and Drug Administration (FDA), for its acronym in English) AZD7442 for emergency use authorization For prophylaxis of COVID-19.
“We have already completed two years of the first reported case of COVID-19. Specially, I have participated in many trials and developed many molecules, But Our country is just as it was at the beginning of the pandemic. We do our job as scientists but ultimately the decision-makers are the health officials. Vaccines have helped us a lot but it certainly hasn’t solved all the problems nor has it helped the entire population. We need a complement ”, End Campos to Infobe.
With two years of plague, the world today faces a perhaps more complex scenario as it will require more diverse and complementary sanitation and epidemiological strategies: Today there are two epidemics in one; coexistence, caused by the original virus and that occurs without vaccination,
Since It is imperative to supplement health strategies with monoclonal and antiviral treatments – such as the recent developments by MSD and Pfizer: Molnupiravir and Paxlovid respectively. These are small pills, they can be mass-produced and patients can take them at home. But part of the impetus for these decisions lies in the hands of the world‘s most emblematic regulators – the North American FDA and the European EMA – who have yet to approve any of these developments under emergency. AZD7442 D AstraZeneca.
In this regard, Mayne Pangalos, Executive Vice President of R&D for Biopharmaceuticals at AstraZeneca, said, “We are making progress in filing applications for regulatory registration worldwide and we are looking to develop a vaccine against SARS-CoV-2 as soon as possible. Hope to be able to provide new option. As much as possible.” And the Cambridge-based drugmaker has agreed to supply 700,000 doses of AZD7442 to the United States if the FDA gives it emergency use authorization and agreements to supply it to other countries.
All avenues – vaccines and treatments – lead to the same final destination: to defeat or at least pierce this epidemic, turning it into an endemic until the greatest number of people worldwide with treatments and vaccines available Global control is not achieved.